Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Envisia Therapeutics
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Controlled Release
- Drug Delivery
- Large Molecule
- Nanotechnology, Chips, etc.